3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
5
Polycystic Ovary Syndrome
2
Obesity
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Triple Negative Breast Neoplasms
1
Tracheal Diseases
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Salivary Gland Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Overweight
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Motor Activity
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Lymphoma
1
Lung Neoplasms
1
Localized Prostate Cancer
1
Leukemia
1
Leiomyosarcoma
1
Interventions
atezolizumab
2
trifluridine tipiracil drug combination
1
selinexor
1
pembrolizumab
1
futibatinib
1
anlotinib
1
Zoledronic Acid
1
Tablets
1
TAS-116
1
Specimen Handling
1
Rosuvastatin Calcium
1
Ramucirumab
1
Midazolam
1
Gemcitabine
1
Fluorouracil
1
Digoxin
1
Dactinomycin
1
Dacarbazine
1
Cisplatin
1
Carboplatin
1
Biopsy
1
Bevacizumab
1
4-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Sarcoma, Alveolar Soft Part
×
Tablets
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled